Analyst Ratings For AnaptysBio Inc (NASDAQ:ANAB)
Today, Wedbush reiterated its Outperform rating on AnaptysBio Inc (NASDAQ:ANAB) with a price target of $138.00.
There are 8 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on AnaptysBio Inc (NASDAQ:ANAB) is Buy with a consensus target price of $128.5556 per share, a potential 45.51% upside.
Some recent analyst ratings include
- 9/18/2018-AnaptysBio Inc (NASDAQ:ANAB) had its Outperform rating reiterated by Wedbush with a $138.00 price target
- 8/8/2018-AnaptysBio Inc (NASDAQ:ANAB) had its Hold rating reiterated by Royal Bank of Canada with a $84.00 price target
- 8/7/2018-AnaptysBio Inc (NASDAQ:ANAB) had its Buy rating reiterated by Jefferies Financial Group with a $121.00 price target
- 7/19/2018-AnaptysBio Inc (NASDAQ:ANAB) has coverage initiated with a Outperform rating and $104.00 price target
- On 4/16/2018 Nicholas Lydon, Director, sold 33,000 with an average share price of $86.88 per share and the total transaction amounting to $2,867,040.00.
- On 8/21/2017 Holdings A/S Novo, Major Shareholder, sold 356,300 with an average share price of $21.10 per share and the total transaction amounting to $7,517,930.00.
- On 8/15/2017 Holdings A/S Novo, Major Shareholder, sold 178,600 with an average share price of $21.16 per share and the total transaction amounting to $3,779,176.00.
- On 8/7/2017 Holdings A/S Novo, Major Shareholder, sold 491,294 with an average share price of $21.12 per share and the total transaction amounting to $10,376,129.28.
- On 8/3/2017 Holdings A/S Novo, Major Shareholder, sold 70,706 with an average share price of $23.31 per share and the total transaction amounting to $1,648,156.86.
- On 7/26/2017 Ventures Vii L P Avalon, Major Shareholder, sold 37,040 with an average share price of $24.35 per share and the total transaction amounting to $901,924.00.
- On 1/31/2017 Healthcare Vii L.P. Frazier, Major Shareholder, bought 400,000 with an average share price of $15.00 per share and the total transaction amounting to $6,000,000.00.
About AnaptysBio Inc (NASDAQ:ANAB)
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033), and PD-1 (TSR-042), as well as a bispecific antibody product candidate targeting PD-1 and LAG-3; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 agonist antibody (CC-90006) that is in Phase 1 trial. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.
Recent Trading Activity for AnaptysBio Inc (NASDAQ:ANAB)
Shares of AnaptysBio Inc closed the previous trading session at 88.35 up +2.24 2.60% with shares trading hands.
